Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826371 | 1.00 | MAPK1 (0.50) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL7334778 | 0.94 | KDM4E (0.50) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL1505593 | 0.86 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1ATMKMT2A | |
| SCHEMBL8806697 | 0.86 | HTT (0.48) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL17111632 | 0.83 | KDM4E (0.49) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL31386800 | 0.83 | KDM4E (0.49) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL41129 | 0.82 | KDM4E (0.51) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL31705858 | 0.82 | KDM4E (0.51) | MAPK1PDGFRBKDRKDM4EL3MBTL1 | |
| SCHEMBL4655755 | 0.82 | CA12 (0.45) | MAPK1KDM4EL3MBTL1KMT2AHTT | |
| SCHEMBL451366 | 0.82 | CYP2C19 (0.50) | KMT2AHTTALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4634178-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313560-A1 | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-5700796-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE, DISEASE CONDITIONS WITH EXCESS RENAL WATER REABSORPTION AND CONDITIONS WITH INCREASED VASULAR RESISTANCE AND CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696112-A | TREATMENT OF CONGESTIVE HEART FAILURE, CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | MAPK1 2745/4885PDGFRB 4224/4885KDR 4855/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | MAPK1 2019/4885PDGFRB 3328/4885KDR 3189/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | MAPK1 2745/4885PDGFRB 4224/4885KDR 4855/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | MAPK1 2248/4885PDGFRB 750/4885KDR 3889/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | MAPK1 4226/4885PDGFRB 4346/4885KDR 1811/4885 |
| US-20250313560-A1 | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors | SOS1, SOS2, RSU1 | MAPK1 59/4885PDGFRB 2003/4885KDR 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.